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A B S T R A C T
Trimetazidine, a novel anti-ischemic agent, is used in the therapy of angina, vertigo and chorioretinal
diseases. It has also been examined for its effect on nociception, inﬂammation and neuroprotection in
various animal models. The present study was designed to investigate the effect of trimetazidine on
electrically induced seizures in mice. Trimetazidine was administered orally in doses of 5, 10 and 20 mg/
kg (single dose) to observe its effect on the increasing current electroshock seizure (ICES) test in mice.
Trimetazidine in 10 and 20 mg/kg doses signiﬁcantly raised the seizure-threshold current in the ICES
test. Further, co-administration of per se ineffective dose of trimetazidine (5 mg/kg, p.o.) with sub-
anticonvulsant dose of nimodipine (10 mg/kg, p.o.) and phenytoin (12.5 mg/kg, p.o.) offered signiﬁcant
protection in the ICES test. These results indicate that trimetazidine possesses signiﬁcant anticonvulsant
activity against electro-convulsions in the mice.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is a complex neurological disorder that affects
approximately 1% of the population worldwide. Currently avail-
able conventional antiepileptic drugs (AEDs) provide control in
only 75–80% of epileptic patients.1 These agents mainly affect
transport of ions across the cell membrane and/or modulate
inhibitory or excitatory neurotransmission.2 A wide array of
adverse effects associated with these agents are a major limitation
for their long term use.3 Therefore, the development of a novel
antiepileptic agent with better efﬁcacy and minimal adverse
effects would be an interesting prospect in the ﬁeld of medical
research.
Calcium ions (Ca2+) play an important role during epileptogen-
esis. It has been noticed that an increase in Ca2+ inﬂux in the cell
triggers seizurogenic activity in the neurons.4 Recently, Ca2+
channel blockers, particularly dihydropyridines per se and with
AEDs have been shown to decrease the incidence of seizures in
various experimental models of epilepsy.5,6
Trimetazidine is a lipophilic piperazine derivative, a drug of
interest in ischemic diseases. It has been found to improve
symptoms and frequency of angina by maintaining Ca2+ homeo-
stasis in the cells.7–9 In ischemic cardiomyopathy, trimetazidine
has been found to prevent accumulation of calcium in cells by
regulating exchange of ions across the membrane.10 It has* Corresponding author. Tel.: +91 11 22592972 75x5704.
E-mail address: drpramod_k@yahoo.com (P.K. Mediratta).
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doi:10.1016/j.seizure.2010.04.001demonstrated anti-oxidant, anti-inﬂammatory, antinociceptive
and gastroprotective properties in various experimental animal
models.11 Several studies have demonstrated that it protects not
only heart8,12 from ischemic injury but also brain,13,14 lung,15
kidney,16 intestine17 and liver.18 A potent neuroprotective activity
of trimetazidine has been observed against stroke in the gerbil
model of transient global ischemia.14 In another study, trimeta-
zidine was found to exhibit anti-excitotoxic activity in vestibular
ganglionic neurons of rat. This anti-excitotoxic activity of
trimetazidine was shown to be mediated via modulation of
AMPA/kainate receptors.19 Most of these studies have focused on
anti-ischemic proﬁle of trimetazidine while data on its possible
neurological actions especially on epilepsy are essentially lacking.
Thus, the objective of the present studywas to explore the possible
effects of trimetazidine on electroshock-induced seizure in mice.
2. Materials and methods
2.1. Animals
Swiss albino male mice weighing 24–35 g were used in the
study. Animals were procured from the Central Animal House,
University College of Medical Sciences, University of Delhi, Delhi.
Animals were housed in groups of six mice per cage
(43 cm  28.6 cm  15.5 cm) with a natural light/dark cycle and
provided with free access to pellet diet and water. All the
experiments were conducted between 9:30 a.m. and 6:30 p.m. in
the neuropharmacology laboratory of the department. Procedures
adopted during experiments on animals and their care werevier Ltd. All rights reserved.
Table 1
Effect of trimetazidine, phenytoin, nimodipine and combinations on ICES test in
mice.
Group (n=8) Treatment Dose
(mg/kg, p.o.)
STC (mA)
I CMC 1% 10ml/kg 14.20.45
II Trimetazidine 5 15.50.50
III Trimetazidine 10 18.71.46*
IV Trimetazidine 20 21.70.95#
V Phenytoin 12.5 15.20.75
VI Phenytoin 25 24.70.36#
VII Nimodipine 10 14.70.64
VIII Nimodipine 20 19.01.30*
IX Nimodipine 40 22.01.25#
X Phenytoin + trimetazidine 12.5 +5 25.70.59#,y,z
XI Nimodipine + trimetazidine 10+5 24.50.73#,y,¥
STC: seizure-threshold current; values are mean S.E.M.
* P<0.01 vs. control (ANOVA followed by Tukey’s test).
# P<0.001 vs. control (ANOVA followed by Tukey’s test).
y P<0.001 vs. II group (ANOVA followed by Tukey’s test).
z P<0.001 vs. V group (ANOVA followed by Tukey’s test).
¥ P<0.001 vs. VII group (ANOVA followed by Tukey’s test).
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Purpose of Control and Supervision of Experiments on Animals
(CPCSEA), India and was approved by Institutional Animal Ethics
Committee, University College of Medical Sciences, University of
Delhi, Delhi.
2.2. Drugs and dosing schedules
The following drugs were used: trimetazidine (Trivedon-20 mg
tabs, Cipla Ltd., Mumbai, India), phenytoin (Sigma St Louis, MO,
USA), and nimodipine (Nimodip 30 mg tabs, USV Ltd., Mumbai,
India). Trimetazidine, phenytoin and nimodipine were suspended
with 1% carboxy methyl cellulose (CMC) in double-distilled water
and administered once orally. Trimetazidine was administered in
doses of 5, 10 and 20 mg/kg while phenytoin was given in doses of
12.5 and 25 mg/kg. Nimodipine was administered in doses of 10,
20 and 40 mg/kg. Control groups were administered with 1%
carboxymethyl cellulose. All drugs were administered in a volume
of 10 ml/kg bodyweight and the animalswere tested 1 h after drug
administration.
2.3. Methodology
2.3.1. Increasing current electroshock seizure test
ICES test, as proposed by Kitano et al.20 and modiﬁed by
Marwah et al.21 was used to determine seizure-threshold current
(STC) for each animal. It is a widely used test to screen the anti- and
pro-convulsant activity of a novel compound. The potential of an
agent to increase seizure-threshold current can be assessed in this
test. It was used in the present study to ascertain the efﬁcacy of
trimetazidine alone and in combination with phenytoin, a
standard antiepileptic drug, and nimodipine, a calcium channel
blocker, against electro-convulsions in mice.
Starting with a current of 2 mA, electroshock was delivered to
each mouse via ear electrodes as a single train of pulses (20 Hz for
0.2 s) with linearly increasing intensity of 2 mA/2 s using an
electro-convulsiometer (Techno, India). The current at which tonic
hind limb extension (HLE) occurred was recorded as the seizure-
threshold current. If no tonic HLE was observed by the current of
30 mA, electroshock was terminated and this cut-off current was
used in the analysis.
2.4. Statistical analysis
The results were expressed as mean  Standard Error of Mean
(S.E.M.). Statistical analysis of the data was done using one-way
analysis of variance (ANOVA) followed by post hoc Tukey’s test. The p-
values less than 0.05 were considered signiﬁcant.
3. Results
3.1. Effect of trimetazidine on increasing current electroshock seizures
test in mice
Single dose administration of trimetazidine (10 and 20 mg/kg),
phenytoin (25 mg/kg) and nimodipine (20 and 40 mg/kg) signiﬁ-
cantly raised the seizure-threshold current as compared to control
group. However, no signiﬁcant elevation in seizure-threshold
current was observed with administration of lower doses of
trimetazidine (5 mg/kg), nimodipine (10 mg/kg) and phenytoin
(12.5 mg/kg) when compared with control.
The combined administration of trimetazidine and phenytoin in
their sub-anticonvulsant doses, i.e. 5 and 12.5 mg/kg, respectively
caused signiﬁcant increase in seizure-threshold current as
compared to control, trimetazidine 5 mg/kg and phenytoin
12.5 mg/kg groups. Similarly, co-administration of trimetazidine(5 mg/kg) and nimodipine (10 mg/kg) in their sub-anticonvulsant
doses signiﬁcantly raised the seizure-threshold current when
compared to control, trimetazidine (5 mg/kg) and nimodipine
(12.5 mg/kg) alone treated groups (Table 1).
4. Discussion
Trimetazidine is a well-tolerated drug, indicated for clinical use
in several ischemia related diseases.7,8 Being lipophillic in nature it
crosses the blood brain barrier.8 Trimetazidine inhibits the
initiation of glutathione production and improves thiol component
level in neuronal cells therefore, has shown beneﬁcial effects on
anti-oxidant enzymes in brain.22 Recently, it has demonstrated
neuroprotective effect on crush injury of sciatic nerve in rats.23
Additionally, it has shown protection against animal models of
inﬂammation, nociception, gastric injury11 and iron-induced
epilepsy.24
In epilepsy it has been noticed that calcium plays an important
role in generating seizures. Extensive literature has highlighted
that Ca2+ is a primary mediator during epileptogenesis and status
epilepticus-induced neurotoxicity.4,25 It is well documented that
epileptic depolarization of neurons is effectively suppressed by
Ca2+ channel blocking agents. The Ca2+ channel inhibition by
dihydropyridines exhibited protection in experimental models of
seizures.6,26 Several animal studies have reported that dihydro-
pyridines by virtue of their brain penetrating property potentiate
the protective efﬁcacy of some antiepileptic drugs like phenytoin,
carbamazepine, valproic acid etc.5,25,27 Various clinical reports
have revealed beneﬁcial effects of certain calcium channel
blocking agents, i.e. nimodipine, cinnarizine and ﬂunarizine as
add-on treatment in epileptic seizures.28,29
In the present study trimetazidinewas tested in doses 5, 10 and
20 mg/kg against electrically induced seizure in the mice. The
results demonstrated that in ICES test trimetazidine in doses of 10
and 20 mg/kg dose signiﬁcantly increased the seizure-threshold
current as compared to control group. Trimetazidine in a dose of
5 mg/kg did not elicit protection when given alone against
electrically induced seizure. However, co-administration of
trimetazidine in 5 mg/kg dose with sub-anticonvulsant dose of
nimodipine 10 mg/kg, a Ca2+ channel blocker signiﬁcantly
increased the seizure-threshold current as compared to control
group. The protection demonstrated by trimetazidine in the
present study is consistent with previous experimental reports
where Ca2+ channel blockers have shown protection against
various convulsive models of epilepsy.6,27,30 The additive effect
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mechanism of action or due to interaction at blood brain barrier.
Transport of various drugs at the blood brain barrier is mediated by
many transporters. These drug efﬂux transporters thought to limit
the drug distribution in brain parenchyma. Recently, it has been
shown that adjuvant treatment with nimodipine restored the
normal hippocampal concentration of phenytoin in phenytoin
refractory epilepsy model in rats which is considered due to its P-
gp inhibiting activity.31 In the present study the additive effect
obtainedmight be due to increased concentration of these drugs at
target site due to decrease efﬂux. Furthermore, the additive effect
obtained may be due to possible similar mechanism of action.
Nimodipine by inhibiting calcium channel has shown antiepileptic
activity in various experimental models. Trimetazidine has also
shown calcium antagonistic action. In a voltage clamp study using
ventricular myocytes of guinea pig trimetazidine blocked the
calcium channel and decreased the peak amplitude of calcium
current.32 Furthermore, it decreased the calcium ion content in the
cytoplasm of undifferentiated HL-60 cell, this inhibitory effect was
considered due to blockade of Ca2+ channel.33
Many studies have demonstrated that conventional AEDs like
phenytoin exert its anticonvulsant action partially due to
interaction with voltage dependent calcium channels.34,35 Schu-
macher et al.36 have observed that phenytoin altered the low
voltage activated Ca2+ channels in cultured hippocampus neurons,
rodent thalamic neurons and neuroblastoma cells. It partially
antagonized the L-type Ca2+ current. In the present study the sub-
anticonvulsant dose of trimetazidine was also co-administered
with a sub-anticonvulsant dose of phenytoin. The combination has
signiﬁcantly increased the seizure-threshold current as compared
to control group. These results are comparable with the effect
obtained with trimetazidine when given alone in higher doses of
10 and 20 mg/kg.
The ﬁndings of the present study suggest that trimetazidine
possesses anticonvulsant activity against electroshock-induced
seizure test in mice, possibly due to modulation of Ca2+ channels.
However, our ﬁndings are preliminary and further chronic,
biochemical and clinical studies are required to explore the exact
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